Teicoplanin, vancomycin, rifampicin: in-vivo and in-vitro studies with Staphylococcus aureus

Groups of mice infected with 3.3 × 108 Stapyhlococcus aureus via the tail vein were treated three days later with rifampicin (13 mg/kg), vancomycin (33 mg/kg), or teicoplanin (33 mg/kg). Rifampicin was the most effective agent (28 out of 29 survivors). Vancomycin and teicoplanin were of equivalent e...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of antimicrobial chemotherapy 1987-05, Vol.19 (5), p.659-662
Hauptverfasser: Carper, Holliday T., Sullivan, Gail W., Mandell, Gerald L.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 662
container_issue 5
container_start_page 659
container_title Journal of antimicrobial chemotherapy
container_volume 19
creator Carper, Holliday T.
Sullivan, Gail W.
Mandell, Gerald L.
description Groups of mice infected with 3.3 × 108 Stapyhlococcus aureus via the tail vein were treated three days later with rifampicin (13 mg/kg), vancomycin (33 mg/kg), or teicoplanin (33 mg/kg). Rifampicin was the most effective agent (28 out of 29 survivors). Vancomycin and teicoplanin were of equivalent efficacy (21 of 29 and 24 of 29 survivors, respectively). When intraleucocytic staphylococci were incubated with rifampicin (1 or 20 mg/l), vancomycin (100 mg/l), or teicoplanin (100 mg/l), rifampicin was the most active drug. Vancomycin and teicoplanin were similar.
doi_str_mv 10.1093/jac/19.5.659
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_77613413</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>77613413</sourcerecordid><originalsourceid>FETCH-LOGICAL-c268t-75a5e5875f1974974ab00d4af201666bae3c46b90fb8aed9d44fe8d0879ff9033</originalsourceid><addsrcrecordid>eNo9kF2L1DAUhoMo67h6563QC_FqO3vSNEnjnawfK-yq6IqLCOE0TdisbVOTdnT-vRlmGDhwXngfDpyHkOcU1hQUO79Hc07Vmq8FVw_IitYCygoUfUhWwICXsubsMXmS0j0ACC6aE3JSKS6qSq3IrxvrTZh6HP14VmxwNGHYml2O3uEw-ZxfF34sN34TChy7fZ5jKNK8dN6m4q-f74pvM0532z6YYMySClyiXdJT8shhn-yzwz4l39-_u7m4LK8-f_h48eaqNJVo5lJy5JY3kjuqZJ0HW4CuRlcBFUK0aJmpRavAtQ3aTnV17WzTQSOVcwoYOyWv9nenGP4sNs168MnYPn9lw5K0lIKymu7Asz1oYkgpWqen6AeMW01B72TqLFNTpbnOMjP-4nB3aQfbHeGDvdy_PPSYDPYuZn0-HbGmolwKyFi5x3ya7b9jjfG3FpJJri9vf-rrH7dfPr2Fa_2V_Qdv0o0R</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>77613413</pqid></control><display><type>article</type><title>Teicoplanin, vancomycin, rifampicin: in-vivo and in-vitro studies with Staphylococcus aureus</title><source>Oxford University Press Journals Digital Archive legacy</source><source>MEDLINE</source><creator>Carper, Holliday T. ; Sullivan, Gail W. ; Mandell, Gerald L.</creator><creatorcontrib>Carper, Holliday T. ; Sullivan, Gail W. ; Mandell, Gerald L.</creatorcontrib><description>Groups of mice infected with 3.3 × 108 Stapyhlococcus aureus via the tail vein were treated three days later with rifampicin (13 mg/kg), vancomycin (33 mg/kg), or teicoplanin (33 mg/kg). Rifampicin was the most effective agent (28 out of 29 survivors). Vancomycin and teicoplanin were of equivalent efficacy (21 of 29 and 24 of 29 survivors, respectively). When intraleucocytic staphylococci were incubated with rifampicin (1 or 20 mg/l), vancomycin (100 mg/l), or teicoplanin (100 mg/l), rifampicin was the most active drug. Vancomycin and teicoplanin were similar.</description><identifier>ISSN: 0305-7453</identifier><identifier>EISSN: 1460-2091</identifier><identifier>DOI: 10.1093/jac/19.5.659</identifier><identifier>PMID: 2956229</identifier><identifier>CODEN: JACHDX</identifier><language>eng</language><publisher>Oxford: Oxford University Press</publisher><subject>Animals ; Anti-Bacterial Agents - pharmacology ; Anti-Bacterial Agents - therapeutic use ; Antibacterial agents ; Antibiotics. Antiinfectious agents. Antiparasitic agents ; Biological and medical sciences ; Glycopeptides - pharmacology ; Glycopeptides - therapeutic use ; Male ; Medical sciences ; Mice ; Mice, Inbred ICR ; Microbial Sensitivity Tests ; Pharmacology. Drug treatments ; Random Allocation ; Rifampin - pharmacology ; Rifampin - therapeutic use ; Staphylococcal Infections - drug therapy ; Staphylococcus aureus - drug effects ; Teicoplanin ; Vancomycin - pharmacology ; Vancomycin - therapeutic use</subject><ispartof>Journal of antimicrobial chemotherapy, 1987-05, Vol.19 (5), p.659-662</ispartof><rights>1987 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c268t-75a5e5875f1974974ab00d4af201666bae3c46b90fb8aed9d44fe8d0879ff9033</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=8215760$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/2956229$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Carper, Holliday T.</creatorcontrib><creatorcontrib>Sullivan, Gail W.</creatorcontrib><creatorcontrib>Mandell, Gerald L.</creatorcontrib><title>Teicoplanin, vancomycin, rifampicin: in-vivo and in-vitro studies with Staphylococcus aureus</title><title>Journal of antimicrobial chemotherapy</title><addtitle>J Antimicrob Chemother</addtitle><description>Groups of mice infected with 3.3 × 108 Stapyhlococcus aureus via the tail vein were treated three days later with rifampicin (13 mg/kg), vancomycin (33 mg/kg), or teicoplanin (33 mg/kg). Rifampicin was the most effective agent (28 out of 29 survivors). Vancomycin and teicoplanin were of equivalent efficacy (21 of 29 and 24 of 29 survivors, respectively). When intraleucocytic staphylococci were incubated with rifampicin (1 or 20 mg/l), vancomycin (100 mg/l), or teicoplanin (100 mg/l), rifampicin was the most active drug. Vancomycin and teicoplanin were similar.</description><subject>Animals</subject><subject>Anti-Bacterial Agents - pharmacology</subject><subject>Anti-Bacterial Agents - therapeutic use</subject><subject>Antibacterial agents</subject><subject>Antibiotics. Antiinfectious agents. Antiparasitic agents</subject><subject>Biological and medical sciences</subject><subject>Glycopeptides - pharmacology</subject><subject>Glycopeptides - therapeutic use</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Mice</subject><subject>Mice, Inbred ICR</subject><subject>Microbial Sensitivity Tests</subject><subject>Pharmacology. Drug treatments</subject><subject>Random Allocation</subject><subject>Rifampin - pharmacology</subject><subject>Rifampin - therapeutic use</subject><subject>Staphylococcal Infections - drug therapy</subject><subject>Staphylococcus aureus - drug effects</subject><subject>Teicoplanin</subject><subject>Vancomycin - pharmacology</subject><subject>Vancomycin - therapeutic use</subject><issn>0305-7453</issn><issn>1460-2091</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1987</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNo9kF2L1DAUhoMo67h6563QC_FqO3vSNEnjnawfK-yq6IqLCOE0TdisbVOTdnT-vRlmGDhwXngfDpyHkOcU1hQUO79Hc07Vmq8FVw_IitYCygoUfUhWwICXsubsMXmS0j0ACC6aE3JSKS6qSq3IrxvrTZh6HP14VmxwNGHYml2O3uEw-ZxfF34sN34TChy7fZ5jKNK8dN6m4q-f74pvM0532z6YYMySClyiXdJT8shhn-yzwz4l39-_u7m4LK8-f_h48eaqNJVo5lJy5JY3kjuqZJ0HW4CuRlcBFUK0aJmpRavAtQ3aTnV17WzTQSOVcwoYOyWv9nenGP4sNs168MnYPn9lw5K0lIKymu7Asz1oYkgpWqen6AeMW01B72TqLFNTpbnOMjP-4nB3aQfbHeGDvdy_PPSYDPYuZn0-HbGmolwKyFi5x3ya7b9jjfG3FpJJri9vf-rrH7dfPr2Fa_2V_Qdv0o0R</recordid><startdate>198705</startdate><enddate>198705</enddate><creator>Carper, Holliday T.</creator><creator>Sullivan, Gail W.</creator><creator>Mandell, Gerald L.</creator><general>Oxford University Press</general><scope>BSCLL</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>198705</creationdate><title>Teicoplanin, vancomycin, rifampicin: in-vivo and in-vitro studies with Staphylococcus aureus</title><author>Carper, Holliday T. ; Sullivan, Gail W. ; Mandell, Gerald L.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c268t-75a5e5875f1974974ab00d4af201666bae3c46b90fb8aed9d44fe8d0879ff9033</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1987</creationdate><topic>Animals</topic><topic>Anti-Bacterial Agents - pharmacology</topic><topic>Anti-Bacterial Agents - therapeutic use</topic><topic>Antibacterial agents</topic><topic>Antibiotics. Antiinfectious agents. Antiparasitic agents</topic><topic>Biological and medical sciences</topic><topic>Glycopeptides - pharmacology</topic><topic>Glycopeptides - therapeutic use</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Mice</topic><topic>Mice, Inbred ICR</topic><topic>Microbial Sensitivity Tests</topic><topic>Pharmacology. Drug treatments</topic><topic>Random Allocation</topic><topic>Rifampin - pharmacology</topic><topic>Rifampin - therapeutic use</topic><topic>Staphylococcal Infections - drug therapy</topic><topic>Staphylococcus aureus - drug effects</topic><topic>Teicoplanin</topic><topic>Vancomycin - pharmacology</topic><topic>Vancomycin - therapeutic use</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Carper, Holliday T.</creatorcontrib><creatorcontrib>Sullivan, Gail W.</creatorcontrib><creatorcontrib>Mandell, Gerald L.</creatorcontrib><collection>Istex</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of antimicrobial chemotherapy</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Carper, Holliday T.</au><au>Sullivan, Gail W.</au><au>Mandell, Gerald L.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Teicoplanin, vancomycin, rifampicin: in-vivo and in-vitro studies with Staphylococcus aureus</atitle><jtitle>Journal of antimicrobial chemotherapy</jtitle><addtitle>J Antimicrob Chemother</addtitle><date>1987-05</date><risdate>1987</risdate><volume>19</volume><issue>5</issue><spage>659</spage><epage>662</epage><pages>659-662</pages><issn>0305-7453</issn><eissn>1460-2091</eissn><coden>JACHDX</coden><abstract>Groups of mice infected with 3.3 × 108 Stapyhlococcus aureus via the tail vein were treated three days later with rifampicin (13 mg/kg), vancomycin (33 mg/kg), or teicoplanin (33 mg/kg). Rifampicin was the most effective agent (28 out of 29 survivors). Vancomycin and teicoplanin were of equivalent efficacy (21 of 29 and 24 of 29 survivors, respectively). When intraleucocytic staphylococci were incubated with rifampicin (1 or 20 mg/l), vancomycin (100 mg/l), or teicoplanin (100 mg/l), rifampicin was the most active drug. Vancomycin and teicoplanin were similar.</abstract><cop>Oxford</cop><pub>Oxford University Press</pub><pmid>2956229</pmid><doi>10.1093/jac/19.5.659</doi><tpages>4</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0305-7453
ispartof Journal of antimicrobial chemotherapy, 1987-05, Vol.19 (5), p.659-662
issn 0305-7453
1460-2091
language eng
recordid cdi_proquest_miscellaneous_77613413
source Oxford University Press Journals Digital Archive legacy; MEDLINE
subjects Animals
Anti-Bacterial Agents - pharmacology
Anti-Bacterial Agents - therapeutic use
Antibacterial agents
Antibiotics. Antiinfectious agents. Antiparasitic agents
Biological and medical sciences
Glycopeptides - pharmacology
Glycopeptides - therapeutic use
Male
Medical sciences
Mice
Mice, Inbred ICR
Microbial Sensitivity Tests
Pharmacology. Drug treatments
Random Allocation
Rifampin - pharmacology
Rifampin - therapeutic use
Staphylococcal Infections - drug therapy
Staphylococcus aureus - drug effects
Teicoplanin
Vancomycin - pharmacology
Vancomycin - therapeutic use
title Teicoplanin, vancomycin, rifampicin: in-vivo and in-vitro studies with Staphylococcus aureus
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-05T16%3A05%3A12IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Teicoplanin,%20vancomycin,%20rifampicin:%20in-vivo%20and%20in-vitro%20studies%20with%20Staphylococcus%20aureus&rft.jtitle=Journal%20of%20antimicrobial%20chemotherapy&rft.au=Carper,%20Holliday%20T.&rft.date=1987-05&rft.volume=19&rft.issue=5&rft.spage=659&rft.epage=662&rft.pages=659-662&rft.issn=0305-7453&rft.eissn=1460-2091&rft.coden=JACHDX&rft_id=info:doi/10.1093/jac/19.5.659&rft_dat=%3Cproquest_cross%3E77613413%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=77613413&rft_id=info:pmid/2956229&rfr_iscdi=true